welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
study id #: NCT00134758
condition: Adenomatous Polyposis Coli, Familial
status: status unknownpurpose:
Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.
Drug: Ursodeoxycholic acid
start date: October 2004
estimated completion: June 2009
last updated: July 29, 2009
phase of development: Phase 2, Phase 3
size / enrollment: 90
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
We designed a randomized double blinded study to evaluate the efficiency of UDCA in the treatment of duodenal adenomas. One hundred patients are planned to be included. Fifty will receive UDCA and fifty a placebo. Three duodenoscopies are planned: one before inclusion, one at the end of the first year of follow-up and one after two years of follow-up at the end of the protocol. These duodenoscopies are associated to endoscopies of the ileal reservoir performed at the time of restorative proctocolectomy and are recorded numerically. Severity of the duodenal adenomas are evaluated according to the SPIGELMAN score. Patients are seen every 6 months. Before each endoscopy, blood samples are collected for biliary acid profile analysis. Moreover, during endoscopies, duodenal fluid and ileal fluid are collected for biliary acid profile analysis, also.
At the end of the follow-up of the last patients included (nov 2008), biliary acid profile analysis will be performed and statistical analysis of the results will be performed.
- SPIGELMAN severity score of duodenal lesion after 2 years of follow-up [ Time Frame:Baseline ] [ Designated as safety issue: No ]
- Cellular proliferation (Ki 67 and PCNA) [ Time Frame: At the baseline, 1 and 2 years ] [ Designated as safety issue: No ]
- Biliary acid profile [ Time Frame: At the baseline, 1 and 2 years ] [ Designated as safety issue: No ]
- Compliance to the treatment [ Time Frame: Every 6 months during 2 years ] [ Designated as safety issue: No ]
- Male or female patients between 18 and 65 years of age
- Weight less than or equal to 100 kg
- Restorative proctocolectomy
- Activated protein C (APC) mutation identified or more than 100 polyps on the colectomy specimen
- SPIGELMAN score of duodenal adenoma greater than or equal to 1
- Efficient contraceptive treatment for pre-menopausal women
- Cooperative patient
- Signed consent
- Social security insurance
- SPIGELMAN score of duodenal adenoma equal to 4 with severe dysplasia
- Hepatic disease
- Intermesenteric desmoid tumour
- Any severe disease
- Daily use during the last 3 months of:
2. non-steroid anti-inflammatory drugs;
expertly curated content related to this topic
- A Study of Guselkumab in Participants With Familial Adenomatous PolyposisThe purpose of this study is to determin...
- Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous PolyposisA Phase 2, randomized, double blind, pla...
- Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal CancerThe principle objective of this study is...
- Chemoprevention in Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) pre...
- Celecoxib and Tauro-Ursodeoxycholic Acid Co-Treatment Inhibits Cell Growth in Familial Adenomatous Polyposis Derived...Chemoprevention would be a desirable str...
- New treatment reduces precancerous polyps in hereditary cancer patientsInheriting a mutation in the APC gene le...